INNOVATION SHOWCASE

MONDAY, OCTOBER 14, 2019

THE LUNDQUIST INSTITUTE

Research with reach.

Welcome to

The Lundquist Institute (formerly
LA BioMed) Innovation Showcase!

This year's event is held in our brand new 78,000 sq ft Medical Research Laboratory (MRL) and is one of the first major events under our new name, The Lundquist Institute for Biomedical Innovation.

Today we are blessed with excellent speakers and 24 highly-curated startup companies. The startups were selected by our stellar selection committee made up of decision makers from active bioscience investors.

We encourage you to stay for the whole program, which will culminate in our fine wine (and craft beer) tasting event - featuring selections picked by your very own Certified Sommelier (me).

We would like to thank our wonderful sponsors, speakers, and startup presenters - and thank you for attending our event!

A special thanks to my assistant Symone Lowery-Hughes who helped me coordinate much of this show. If you see her today please thank her and wish her good luck as she is just starting The Lundquist PhD program in Translational Research! We will miss her!

We also have Rubayath Mohsen, MS in attendance from the Business Development and Technology Transfer team - please introduce yourself to her. She does fantastic work and keeps me sane. Rubayath manages the Lundquist's patent portfolio from disclosure to licensing. She is available to discuss any BD opportunities for our patented technologies or information on our spin-out companies.

Finally, please seek out Gary Olsem today. Gary is the Site Director for our incubator, BioLabs LA (on the 3rd floor directly above you). He will be giving tours of the space – please see the sign up sheets in the lobby. I strongly encourage you to see the space, even if you have previously. We are open for business!

Best,
Keith Hoffman
Senior Vice President of Business Development and Technology Transfer


Keith Hoffman


Symone Lowery-Hughes


Rubayath Mohsen


Gary Olsem



Contents

Inform.

Schedule

10:00 AM	11:00 AM	REGISTRATION AND NETWORKING
11:00 AM	11:50 AM	**Keith Hoffman** "Welcome, Incubator, Biotechnology Park, and Details for Today" **John Wetherell** "At a Crossroads: Challenges and Opportunities in an Evolving Landscape" **David Meyer** "The Lundquist Institute: Research with reach." **The Honorable Mark Ridley-Thomas** "The County Vision for Bioscience in LA" **Jennifer Landress** "The California Lifescience Ecosystem"
11:50 AM	12:00 PM	BREAK / MOVE TO PRESENTATION ROOMS
12:00 PM	1:00 PM	**Session 1A - Therapeutics Presentations** / Main Room **Forte Biosciences, Inc.** **C-Reveal Therapeutics** **MyoGene Bio** **Hillhurst Biopharmaceuticals** **Session 1B - Medical Devices and Other Presentations** / Board Room **ImaginAb** **Lucid Science** **CBio** **Raydiant Oximetry**
1:00 PM	1:55PM	LUNCH / OUTSIDE
1:55 PM	2:55 PM	**Keynote Panel** / Main Room **"The People Your Startup Will Meet: From Seed to Exit."** This panel consists of three early stage investors (Seed to Series A), two Series B and C investors, and a pharma potential partner/acquirer. **Sean Harper, Helen Kim, Bethany Mancilla, Kwame Ulmer, Frank Stonebanks, Luke Hayes, and Keith Hoffman** (moderator).
2:55 PM	3:05 PM	BREAK
3:05 PM	4:05 PM	**Session 2A - Therapeutics Presentations** / Main Room **MD2** **Origami Therapeutics** **Navega Therapeutics** **Lenire Biosciences** **Session 2B - Medical Devices and Other Presentations** / Board Room **Avails** **Cactus Medical, LLC** **Catalia Health** **Stasis**
4:05 PM	4:15 PM	BREAK
4:15 PM	4:45 PM	Main Room **Susie Harborth** "Lessons Learned from 'The Bench Trenches'" **Rohit Shukla** "The Impact of Business Mentoring on Emerging Science-Based Enterprises"
4:45 PM	4:50 PM	BREAK / MOVE TO PRESENTATION ROOMS
4:50 PM	5:50 PM	**Session 3A - Therapeutics Presentations** / Main Room **SUMO Biosciences** **Viscient Biosciences** **Winsantor** **Cell Care Therapeutics** **Session 3B - Medical Devices Presentations** / Board Room **Veriskin** **Triton Biosystems** **Genemod** **Greenwings**
6:00 PM	7:30 PM	RECEPTION **"Fine wine tasting", craft beers, delicious food, and poster session**

Maps

The Lundquist Institute / Harbor-UCLA Medical Center



Medical Research Laboratory (MRL) Building



Speaker Profiles



Bethany Mancilla

Vice President, Corporate Development, Kite Pharma a Gilead Company

Bethany Mancilla has nearly 30 years of corporate development experience. She is currently the Vice President of Corporate Development at Kite Pharma. Bethany joined Kite in April of 2019 and oversees search and evaluation, licensing, collaborations, equity investments and M&A. Prior to her role at Kite, Ms Mancilla was the Chief Business Officer for Cue Biopharma a Cambridge based, biotech company developing proprietary biologics to selectively modulate antigen specific T cells to treat cancer and autoimmune diseases. At Cue she was responsible for corporate strategy, financing, and business development including spear-heading a multi-target co-development and co-commercialization agreement with LG Chem Life Scievnces. From April 2012 to August 2018, Ms. Mancilla held increasing roles of responsibility at Amgen most recently as Vice President of Business Development. During her tenure at Amgen she led the execution of a number of partnerships including immuno-oncology collaborations with Merck, neuroscience collaborations with Novartis and a multi-product cardiovascular collaboration with Servier. In 2015, she was selected as a top woman at Amgen who helped build the company's history and is impacting the world of science, technology, and business.

Prior to joining Amgen, Ms. Mancilla served as the Vice President of Business Development and Alliance Management for Micromet where she was responsible for negotiating the multi-target BiTE® immune-oncology antibody collaboration with Amgen which ultimately led to the acquisition by Amgen. Earlier in her career Bethany was the head of Business Development for Gene Logic responsible for establishing several multi-million-dollar partnerships with major pharmaceutical companies including Pfizer, Roche, Wyeth, Lilly, Organon, Solvay and Abbott.

Ms. Mancilla began her career as the Director of Business Development for BCM Technologies, a subsidiary of Baylor College of Medicine, where she was involved in the creation and financing of four start-up biotechnology companies. Ms. Mancilla received an M.B.A. from the University of Houston and a B.A. from the University of Colorado.

David I. Meyer, Ph.D.

President and Chief Executive Officer, The Lundquist Institute

Dr. Meyer is Professor Emeritus at the David Geffen School of Medicine at UCLA. He has served as LA BioMed's President and CEO since 2009. Prior positions in research administration include serving as EVP Research at the House Ear Institute (2008-09) and as Vice President for Research and Scientific Affairs at the Cedars-Sinai Medical Center (2004-2007). He has had an active and productive career in research, first at the University of Basel, Switzerland as an Instructor (1973-79), then at the European Molecular Biology Laboratory in Heidelberg Germany as a Research Group Leader in the Cell Biology Program (1979-1987), followed by appointment as Professor of Biological Chemistry at the UCLA School of Medicine (1987-2005). Aside from teaching and research, Dr. Meyer served as Associate Dean for Basic Science and then as Senior Associate Dean for Graduate Studies at UCLA. Dr. Meyer's research into the molecular mechanism of membrane biogenesis and secretion has resulted in numerous peer-reviewed publications and reviews, including articles in Nature, Cell, and The Journal of Cell Biology. Dr. Meyer is a native of Los Angeles, having graduated from Los Angeles High School and earning both his bachelor's and doctoral degrees at UCLA.

Frank Stonebanks

Managing Partner, KickFlip BioVentures

Currently Founder / Managing Partner, KickFlip BioVentures LP, early stage biotech VC exclusively focused on so cal in partnership with top universities
Executive in Residence, UCSD (pro bono)
Former Venture Partner, Lumira Capital
Former Senior Advisor, NovaQuest Capital Management
Former Senior Advisor, IBM Healthcare M&A and Fund to Fund Co-Head (Limited Partner)
Former CBO at Ontario Institute for Cancer Research, Head, Seed Fund
Former GM, J&J, JJDC (J&J investment arm) and Co-Founder,

J&J Internal Ventures (precursor to J&J Innovation/JLABS)
Former Head, Licensing, NABI Biopharmaceuticals
3 x biotech CEO

- Triphase LP ($1.5b deal w Celgene, successful exit in 2016)
- Macroflux (J&J spin out, raised $90 mm)
- Cynvec (NYU spin out of oncolytic viral vector, led through IND/Ph I)

25 years of senior operating and investing experience, from sales, to domestic mktg, global mktg, general management and advisory)
MBA Saint Joseph's University
BA Exercise Physiology University of Victoria
Active angel investor in southern California (7 deals in last 3 years)
Milken Foundation Scholars Program Mentor (pro bono)

Jennifer Landress

Sr. VP and Chief Operating Officer, Biocom

Jennifer Landress, an experienced executive with more than 20 years' experience in budget management, operations, membership, marketing and event development and execution is the Sr. VP and Chief Operating Officer for Biocom. Prior to this she held the position of Vice President of Corporate Relations.

Ms. Landress oversees the budget, management and goals development for the organization. Additionally, she leads the organization's capital development and events departments to identify opportunities for increased visibility for California's life science companies as well as the growth of the organization statewide. She is responsible for the following organization initiatives: Capital Development, Board management and International.

Prior to her employment at Biocom, she was Director of Operations of the Biotechnology Industry Organization (BIO), the world's largest biotechnology organization with more than 1,000 members worldwide.

Ms. Landress has a Bachelor of Arts Degree in English from Bucknell University. She resides in San Diego with her husband, Bo, and three children.



John Wetherell

Partner, Pillsbury Winthrop Shaw Pittman LLP

Dr. Wetherell has over 25 year's experience in intellectual property law. His counseling experience includes intellectual property acquisition, transactional due diligence, patent infringement and validity analyses, freedom-to-operate opinions, as well as licensing and strategic counseling. Dr. Wetherell's patent prosecution experience includes obtaining U.S. and foreign protection in biotechnology areas such as molecular biology, immunology, nanotechnology, medical diagnostics, microbiology and pharmacology.

Dr. Wetherell received a B.S. degree in Chemistry, and a Ph.D. degree in Microbiology/Immunology, both from the University of Florida, and a J.D. degree from Seton Hall University School of Law. He conducted post-doctoral research, including studies on the humoral and cellular immune responses in periodontal disease, at Forsyth Institute in Boston, where he concurrently held an NIH post-doctoral fellowship and a Young Principal Investigator's award. Before becoming an attorney, he gained extensive experience as a research scientist and manager during his five-year tenure in the biotechnology industry.

At Pillsbury, Dr. Wetherell is Head of Intellectual Property in the San Diego Office, Co-Chair of the National Life Science Practice Group, and Chair of the Stem Cell Outlook and Planning Effort (SCOPE). He is also the author of the chapter on "Patent Protection of Stem Cell Innovations" in the latest edition of "Perinatal Stem Cells," published by Elsevier Press. He also serves on the Board of Directors of the Cystic Fibrosis Foundation.

In addition, he serves as Legal Advisor for the Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences.

Dr. Wetherell has written and lectured extensively on patent law, strategy, and related transactional issues for many organizations and institutions around the world.

Keith Hoffman

Senior Vice President, Business Development and Technology Transfer, The Lundquist Institute

Dr. Hoffman is responsible for the development of commercialization opportunities for LA BioMed's intellectual properties, capabilities and expertise. Prior to LA BioMed, Dr. Hoffman held senior management roles (COO, CBO, VP) in business, corporate, science, and intellectual property development for biotechnology, healthcare data, medical device, and consumer product companies. As part of those efforts Dr. Hoffman drafted, and assisted in the prosecution of, over 70 patents. Most recently, he was part of the founding team at Advera Health Analytics where he developed and helped monetize big data platforms that provide real world side effect data on all FDA approved drugs.

Dr. Hoffman is a native San Diegan who earned both his B.S. in Biology and Ph.D. in Neuroscience from UC Irvine in the laboratory of Dr. Gary Lynch. His research at Irvine focused on the molecular basis of learning and memory with an emphasis on how neural cell adhesion molecules may modulate synaptic architectures.

Helen S. Kim

Managing Director, Vida Ventures

Ms. Kim has over 27 years of experience in leadership roles in biotechnology. Most recently, Ms. Kim was a Partner at The Column Group. Prior, Ms. Kim served as Executive Vice President of Business Development at Kite Pharma, Inc. where she led all business and corporate development initiatives successfully selling Kite Pharma to Gilead in 2017.

Previously, Ms. Kim served as Strategic Advisor of NGM Biopharmaceuticals, Inc. from January 2012 through November, 2014. Ms. Kim served as the Chief Business Officer at NGM Biopharmaceuticals, Inc. from August 2009 to January 2012. Prior to NGM, she was the Chief Executive Officer and President of Kosan Biosciences where she restructured and repositioned the company prior to successfully selling the company to Bristol-Myers Squibb in 2008. Ms. Kim's additional industry experience includes executive positions at Affymax, Onyx Pharmaceuticals and Chiron Corporation. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago.

Ms. Kim currently serves on the Board of Directors for Assembly Biosciences, Applied Molecular Transport, Exicure, Inc., A2 Biotherapeutics and Neogene.

Kwame Ulmer

Venture Partner, Wavemaker Three-Sixty Health

Kwame brings nearly twenty years of experience evaluating medical technologies in the government and private sector, and serving in senior operating roles at medical device companies. He has personally evaluated more than 1,000 medical technologies in his career. Kwame spent 12 years at the U.S. Food and Drug Administration (FDA) in progressive leadership roles, including Deputy Director and Branch Chief. He also served as Vice President, Regulatory Affairs and Quality Assurance at Implant Direct, a Danaher Corporation operating company. He is a member of the Executive Committee of Tech Coast Angels (LA), the world's largest angel investing network. Kwame earned his B.S. in Physics from Lincoln University, and has two Masters degrees from University of Virginia, in Materials Engineering and Business Administration.

Luke Hayes

Co-Founder and Managing Director, Torrent Ventures

Luke Hayes is Co-Founder and Managing Director at Torrent Ventures. Luke has been active in venture investing in Los Angeles for more than a decade and loves the adventure of working with early stage companies.

Luke's work in life sciences goes back nearly 20 years when he was responsible for developing licensing opportunities for a micelle-based drug delivery technology. Since then he has had business development responsibilities for clients such as Lilly, Abbott, and Sigma-Aldrich in addition to serving as an advisor for Roswell Biotechnologies, a genetic sequencing company. Luke is a firm believer that an increase in global healthcare demand over the coming decades will spur massive amounts of innovation.

Luke earned a B.S. in Chemical Engineering from Brigham Young University and an M.B.A. from the UCLA Anderson School of Management. Luke lived in Brazil for two years and, when not immersed in venture investing, enjoys wrestling with

his four boys, volunteering in his local church congregation, and tagging along with his wife, Reagan, on her work trips to Vietnam.

The Honorable Mark-Ridley Thomas

Los Angeles County Board of Supervisors, Second District

Since he was overwhelmingly elected in 2008, and reelected in 2012 and 2016 to the Los Angeles County Board of Supervisors, Mark Ridley-Thomas has distinguished himself as an effective leader for more than two million Second District residents. Supervisor Ridley-Thomas authored and led LA County's unprecedented effort to end homelessness through Measure H. He is a board member of the Los Angeles County Metropolitan Transportation Authority, the Los Angeles Memorial Coliseum Commission and LA Care, the nation's largest publicly operated health plan.

Prior to his election to the Board of Supervisors, Supervisor Ridley-Thomas served the 26th District in the California State Senate, where he chaired the Senate's Committee on Business, Professions and Economic Development. While in the Senate, he served as Chair of the California Legislative Black Caucus in 2008 and led the Caucus in unprecedented levels of cooperation and collaboration with counterparts in the Latino and Asian-Pacific Islander Legislative Caucuses.

Mark Ridley-Thomas was first elected to public office in 1991 and served with distinction on the Los Angeles City Council for nearly a dozen years, departing as Council President pro Tempore. He later served two terms in the California State Assembly, where he chaired the Jobs, Economic Development, and Economy Committee and Chaired the Assembly Democratic Caucus. His legislative work addressed a broad range of issues with implications for economic and workforce development, health care, public safety, education, budget accountability, consumer protection and civic participation. He is widely regarded as the foremost advocate of neighborhood participation in government decision-making by virtue of his founding of the Empowerment Congress, arguably the region's most successful 27-year initiative in neighborhood-based civic engagement. Ridley-Thomas' political career was preceded by a decade of service as the executive director of the Southern Christian Leadership Conference of Greater Los Angeles (1981-1991).

The Supervisor graduated from Manual Arts High School (Class of 1972) and then earned BA and MA degrees along with secondary and adult education credentials from Immaculate Heart College. Supervisor Ridley-Thomas went on to receive his Ph.D. in Social Ethics from the University of Southern California focusing on Social Criticism and Social Change.

He is married to Avis Ridley-Thomas, Co-Founder and Director of the Institute for Non-Violence in Los Angeles. They are the proud parents of Sinclair and Sebastian, both Morehouse Men. Sinclair earned an MBA degree at USC's Marshall School of Business, works in the investment banking industry, and resides in San Francisco with his wife Shaunicie, an attorney, and 2-year-old son Duke Flynn. Sebastian formerly represented California's Fifty-forth Assembly District (12/05/13-12/31/17). He will now turn his attention to political empowerment, millennial civic engagement, and training a new generation of leaders throughout the state of California as Chief Strategist for the African American Voter Registration, Education, and Participation Project while completing an MSW in Social Change and Innovation at USC's Dworak-Peck School of Social Work.

Rohit Shukla

Founder & CEO, Larta Institute

Rohit Shukla, Founder and CEO of Larta (www.larta.org) is a nationally recognized expert on commercialization, and enterprise and science-based innovation. Since he founded Larta in 1993, he has advised governments, multilateral organizations, communities and entrepreneurs around the world. He has developed initiatives that expand entrepreneurship, promote commercialization and enhance the competitiveness of regions.

Larta Institute, under his direction, has established national-scale programs in the life sciences, agricultural biotechnology and food, and cleantech and energy to assist entrepreneurs bring innovative products and services to today's dynamic marketplace. These sectors underscore Larta's commitment and mission to "feed, fuel and heal the world." In the biosciences, he designed and developed the NIH-funded Commercialization Accelerator Program (CAP) in 2004, which has evolved to become a well-recognized national program for NIH SBIR and STTR grantees. This national program is focused on commercialization of federally-funded research. It

has a strong track record in all aspects of commercial success, including acquisitions, investment and collaboration. Larta conducts several other similar programs for federal agencies, including NSF, USDA, NIST and DOE. Since 2004, over 3000 companies have graduated from Larta's national and global commercialization programs.

He has also consulted with OECD, initiatives in Romania, Malaysia, Australia, New Zealand, Japan, Korea, Sweden, Finland and a number of other countries.

He has a Master's in Social and Political Sciences from the University of Cambridge, U.K. and a Master's in Communications Arts and Sciences from Loyola Marymount University, Los Angeles. He developed and taught the first course in Startup Management for the MBA program at the Graziadio School at Pepperdine University Los Angeles. He currently serves on the board of BioLA, a new organization established as an initiative of the County of Los Angeles. He is the board chair of Public Policy Charter School, which serves underserved kids in South Los Angeles.

He speaks to audiences around the world on subjects ranging from commercialization and innovation to globalization and entrepreneurship.

Sean Harper

Managing Director, Westlake Village BioPartners

Named by Time as one of the 50 most influential people in healthcare in 2018, Dr. Harper has helped bring well over a dozen novel therapies to patients during his career. In areas as diverse as oncology, osteoporosis, cardiovascular disease and migraine, Harper's passion for science and medicine has benefited millions of patients worldwide.

Harper brings a rare breadth of experience in both basic research and as a practicing physician. He has led a wide range of clinical research programs, from early translational trials to global outcomes studies. As co-founding managing director of Westlake Village BioPartners, Harper identifies promising new therapies and technologies and builds companies to address significant unmet medical needs.

From 2002 to 2018, Harper worked for Amgen, rising to become head of R&D in 2012, where he managed investments of more than $3.5 billion annually, applying breakthroughs in science to address some of society's biggest health challenges.

Susie Harborth

General Partner and CFO, BioInnovation Capital

Susie is General Partner and CFO of BioInnovation Capital, an early-stage venture capital firm; COO of BioLabs, a national network of coworking spaces; and leads Southern California strategy with BioLabs LA at The Lundquist and BioLabs San Diego sites. From 2010-2014, Susie was CFO at GnuBIO, a sequencing start-up, which was acquired by Bio-Rad Laboratories in 2014. Prior to joining GnuBIO, Susie launched Cequent Pharmaceuticals and Boston Heart Diagnostics (BHDx). Susie is on the Advisory Board at LabCentral, a biotech co-working space in Massachusetts and co-founded Launch Bio, a non-profit organization focused on STEM education, social impact, innovation and inclusive entrepreneurship. She is focused on emerging areas of biotechnology, including orphan and rare disease, genomics, diagnostics, women's health and personalized/precision medicine.

Prior to Cequent, Susie focused on public life science companies at SVB Leerink (formerly Leerink Swann), a healthcare investment bank, where she was responsible for operations of the institutional sales trading department and was a licensed stockbroker (Series 7 and 63). She received her masters in biology from Harvard University and a degree in business/finance from CSU, Long Beach. Her graduate research was conducted at Massachusetts General Hospital in the field of breast cancer diagnostics. She is a recipient of the Biocom Catalyst Award and was named a "Woman to Watch" by the Boston Business Journal.

Startup Company Presenters

Avails • C-Reveal Therapeutics • Cactus Medical • Catalia Health • Cbio • Cell Care Therapeutics
Forte Biosciences • Genemod • Greenwings • Hillhurst Biopharmaceuticals • ImaginAB • Lenire Biosciences
Lucid Science • MD2 • MyoGene Bio • Navega Therapeutics • Origami • Raydiant Oximetry • Stasis
SUMO Biosciences • Triton Biosystems • Veriskin • Viscient Biosciences • Winsantor

Therapeutics:

C-Reveal Therapeutics

C-Reveal Therapeutics is a Linden Lake Venture Capital molecular medicine portfolio company formed in August 2019 which aims to develop proprietary selective and potent small molecule inhibitors of several tumor specific phosphatase targets identified and validated at Harvard Medical School and the Massachusetts General Hospital (HMS/MGH). These inhibitors will disable a key novel tumor immune cloaking mechanism, increase antigen load and thus exposing the tumors to endogenous immune responses. C-Reveal's drugs will be applicable to a broad spectrum of cancers and potentiate other cancer therapies such as checkpoint inhibitors, cancer vaccination, T cell therapies and even traditional chemotherapy treatments. C-Reveal's CEO is Thomas Haag (co-founder and acting CEO of PhosImmune, acquired by Agenus, Inc.) and its Scientific Co-Founders are Professors Mark Cobbold (co-founder Gritstone Oncology and PhosImmune), Keith Flaherty (co-Founder Loxo Oncology, acquired by Eli Lilly) and Cyril Benes, all of HMS/MGH.

Cell Care Therapeutics (www.cell-care.com)

Cell Care Therapeutics is a preclinical stage biotechnology company developing a breakthrough manufacturing platform to produce biologics derived from the secreted proteins and exosomes of pericytes, also known as mesenchymal stromal cells (MSCs). Unlike traditional cell transplantation approaches that require cryopreservation, Cell Care's cell-free biologic is shelf stable and easily delivered to patients in any clinical setting. The signaling molecules of pericytes/MSCs maintain the health of the blood-barrier by regulating immune cells and stabilizing blood vessel tight junctions. Cell Care technology targets diseases where pericyte loss leads to breakdown of the blood barrier (i.e. diabetic retinopathy, traumatic brain injury, inflammatory bowel disease). The company has brought together a world class team of regenerative medicine and ophthalmology experts, generated compelling animal data in multiple animal models, and developed a clinical scale manufacturing process. A total of $10M has been invested into the technology to date. The company is actively raising its Series A to advance the technology through an IND filing.

Forte Biosciences

Forte Biosciences, in collaboration with the NIH, is developing a topical live bio-therapeutic for the treatment of inflammatory skin diseases including mild, moderate and severe atopic dermatitis with a focus on pediatrics. The topical therapy was developed based on the extensive work performed at NIH in characterizing the microbiome of the skin. A phase 1/2a study, including pediatric patients 3 years old and older, has completed. The full dataset provides excellent clinical activity and safety validation and is available under CDA. The phase 2 trial is expected to initiate in early 2020. There is a significant unmet need for therapies to treat pediatric atopic dermatitis and in particularly to spare the pediatrics from steroid exposure. Forte Biosciences has assembled a world class pediatric dermatology team including Prof. Amy Paller (lead author on the Eucrisa publication), Prof. Eric Simpson (lead author on the Dupixent publication) and Prof. Laurence Eichenfield (editor-in-chief of Pediatric Dermatology and Chief of Pediatric Dermatology at Rady Children's Hospital). The team also includes Carmen Rodriguez (former head of regulatory affairs for Anacor for the Eucrisa program), Dan Burge (headed clinical development at Dermira) and Hank Talbot (headed manufacturing and quality at Mycogen, Dow and Pfenex with many years of experience with bacterial manufacturing systems).

Hillhurst Biopharmaceuticals

(www.hillhurstbio.com)

Hillhurst Biopharma is a near-clinical stage company focused on hematologic and neurologic disorders. Its lead product, HBI-002, for sickle cell disease (SCD) is IND-ready, with Phase 1 clinical studies planned for early 2020, and represents a $1.4B revenue opportunity. It also has preclinical indications and assets in development for Parkinson's disease and kidney transplant. The HBI-002 drug product enables the chronic therapeutic use of orally administered carbon monoxide (CO). The safety, tolerability, and efficacy of CO in SCD in other delivery forms has been demonstrated by others in 4 clinical trials, and the tolerability and safety of CO have been demonstrated in 18 clinical trials by others, but delivery issues

have prevented the therapeutic use of CO until now. Hillhurst has raised over $5.5 MM in funding to date, including both angel and NIH SBIR funding, and has both patent and orphan drug protection. Hillhurst is led by a highly experienced executive team.

Lenire

Lenire was founded in mid-2018 to develop novel therapies for treatment-resistant anxiety in Fragile X Syndrome (FXS), the most common inherited cause of mental retardation (and autism) that afflicts over 120,000 men and women in the US. Severe, treatment-resistant anxiety is the most disruptive, hard to manage, and costly symptom of FXS. Families of FXS patients incur an additional $33,000/yr in total healthcare costs related to FXS treatment. Lenire will take an entirely novel approach to treating this devastating aspect of FXS prompted by new insights made by our co-founder on the pathobiology of treatment-resistant FXS anxiety. Based on these findings, Lenire has identified underlying disease mechanisms that can be targeted by existing Phase II-tested drugs developed for other indications. Lenire will in-license a candidate for immediate clinical repositioning in FXS anxiety. Our planned 2020 clinical trial will be a Phase Ib trial in adult FXS subjects that includes improved behavioral and quantitative neurological readouts of efficacy developed by our CMO, a world leader and KOL in FXS clinical trial design. We are raising $5MM to complete this trial and design our Phase II study. FDA approval of our targeted treatment for FXS anxiety will comprise the first therapy for FXS world-wide.

MD2 (www.md2bio.com)

MD2 Biosciences is developing a small molecule beta-catenin inhibitor as therapeutic for colorectal cancer and other cancers. MD2 uses a proprietary 'Artificial Intelligence Platform Technology' to identify small molecule hits to target 'Transcription Factors.' MD2 founding team brings a strong background in small business administration, drug discovery, and development experience to enable therapeutic programs. MD2 founded in 2015, located in San Diego, CA.

MyoGene Bio (www.myogenebio.com)

MyoGene Bio is a biotechnology startup dedicated to improving the lives of patients with muscle disease through the development of cutting-edge therapies. Co-founder and CEO, Dr. Courtney Young, has extensive muscle research experience and is inspired by her cousin, Christopher, who was diagnosed with Duchenne muscular dystrophy in 2008. Co-founders Dr. Melissa Spencer and Dr. April Pyle have led important pre-clinical and clinical research in the muscle field during their tenure as professors at UCLA. Our first product (SPY-DYS45-55) is a gene editing platform designed to permanently remove a mutational hotspot in the gene that causes Duchenne muscular dystrophy. We have demonstrated SPY-DYS45-55 restores the dystrophin protein otherwise lacking in Duchenne in human cells and mouse models. Importantly, SPY-DYS45-55 is expected to create a very functional protein and be applicable to ~50% of all Duchenne patients, making it advantageous over exon skipping or other CRISPR therapies that only target single exons (13% or less of patients). Thus, SPY-DYS45-55 would be applicable to ~190,000 Duchenne patients worldwide. MyoGene Bio has been awarded 3 grants totaling $2M and is currently seeking additional seed funding. We are driven by our passion and dedication to making a difference in the lives of patients with muscle disease in order to help boys like Christopher.

Navega Therapeutics (www.navegatx.com)

Navega Therapeutics is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. At Navega, we have developed a patented, non-permanent therapy to target pain that is non-addictive, highly specific, and long lasting. So how does this work? We were inspired by nature: there are humans that have a mutation in their genome that feel no pain whatsoever. We have imitated this process by developing a novel gene therapy to target pain in a non-addictive way. In our proof of concept, we demonstrated that the mice that received our therapy have increased pain tolerance and lower pain levels for weeks. We have validated our approach in three different pain models: inflammatory pain, chemotherapy-induced neuropathic pain and visceral pain. Navega has recently been awarded two SBIR grants, from the National Cancer Institute and from the National Institute of Neurological Disorders and Stroke as part of the Helping to End Addiction Long-term Initiative, or the NIH HEAL Initiative—a program that aims to improve treatments for chronic pain. Navega was also recognized as a 2019 TechConnect Defense Innovation Awardee by the Department of Defense. At Navega, we believe patients should not have to decide whether they live a life with pain or one with a risk of addiction.

Origami Therapeutics, Inc.
(http://origamitherapeutics.com/)

Origami Therapeutics, Inc. is a discovery-stage company pursuing a market disruptive approach to treating neurodegenerative diseases. Origami plans to generate a pipeline of small molecule therapeutics that prevent or delay the onset and the progression of neurodegeneration by targeting the underlying genetic cause of disease. Leveraging the Founder's experience in discovering transformational therapies for Cystic Fibrosis that stabilize the conformation of the disease-causing protein, the Company's focus is to treat neurodegeneration by preventing toxic protein misfolding, thereby maintaining and restoring normal function and physiologic balance. The company is validating its technology by progressing its set of chemical assets, identified using its proprietary screens, towards in vivo proof of concept studies. The initial indication is Huntington's disease (HD), a rare, incurable monogenic disease that strikes at the peak of life and for which there is currently no effective treatment. The team has over 80 years of drug discovery and development experience, contributing to multiple marketed drugs garnering > $4B in sales, > 30 clinical assets, >$800M in VC funding, non-dilutive funding and asset sales, and management of budgets of > $50M.

SUMO Biosciences

SUMO Biosciences discovers and develops small molecule allosteric inhibitors to target ubiquitin-like post-translational modifications. Our current focus is on small molecule inhibitor drugs that activate anti-tumor immunity while inhibit c-Myc-dependent oncogenesis pathways and inhibit cancer stem cell maintenance and self-renewal through inhibiting the activating enzyme catalyzing small ubiquitin-like modifications.

Viscient Biosciences
(www.viscientbiosciences.com)

Viscient Biosciences is a San Diego-based biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to discover and develop drugs across a range of therapeutic areas with significant unmet medical need. By leveraging our expertise in complex, three-dimensional disease models comprised of human cells and complex analytical methods, we are able to drive drug discovery in a previously unavailable context, leading to a better understanding of disease and an improved opportunity to impact patients' lives. Founded by a combination of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is initially conducting discovery and development work in non-alcoholic steatohepatitis ("NASH").

WinSanTor (https://winsantor.com)

WinSanTor Inc. is a clinical-stage biotechnology company focused on the discovery and development of treatments for peripheral neuropathies, including diabetic peripheral neuropathy, chemo- and HIV-induced peripheral neuropathy, and others. Named after the city of each of the founders: Winnipeg, San Diego, and Toronto, WinSanTor was incorporated in 2011 to capture the transformative discoveries originally developed and patented at the University of Manitoba, the University of California at San Diego, and the University of Toronto. Our research has been supported by leading stakeholders in the field, including the Juvenile Diabetes Research Foundation, National Institute of Diabetes and Digestive and Kidney Diseases (at the National Institutes of Health) and the Canadian Institutes of Health Research, in response to the lack of treatments (or potential treatments) for diabetic neuropathy.

Medical Devices / Other:

Avails Medical (https://availsmedical.com)

Avails Medical, Inc. is an in-vitro diagnostics company developing an eQuant/eAST platform. This platform utilizes electrical bio-sensor technology for phenotypic pathogen quantification (eQuant) and antibiotic susceptibility testing (eAST) directly from a positive blood culture of patients with sepsis, reducing AST testing from days to as fast as 4 hours, providing clinicians with actionable results of proper antibiotic therapy days earlier. This improves patient's health outcomes, decreases mortality rates and reduces healthcare costs.

Cactus Medical (www.cactus-medical.com)

Cactus Medical, LLC is developing the new standard of care in pediatric ear infection diagnostics. Cactus' optical

tympanometry is a revolutionary new technology that optically detects the hallmark of middle ear infection at the push of a button. Optical tympanometry is 98% accurate, works through earwax when needed, and has been validated in a clinical study at UC Irvine and the La Veta Surgery Center. Cactus has integrated its technology into the familiar otoscope and will begin a second clinical study later this year. In the past year Cactus has raised nearly $500K to support development and clinical work from NSF, NIH, and CTIP (FDA sponsored pediatric device consortium). Cactus will enter the marketplace upon 510(k) clearance of its ear infection diagnostic, followed by non-invasive tests for bilirubin and strep throat.

Catalia Health (www.cataliahealth.com)

Catalia Health is a chronic disease care management company that gives every patient the experience of having support 24/7. Our AI-driven platform creates a conversation on the fly for each patient each time. Our easy-to-deploy programs are designed around specific disease states. Our pharma and healthcare system customers are able to get incredibly granular care and outcome data on these patients. They pay us on a per-patient per-month basis, the same as for existing programs that provide one or two calls a month to a patient. Customers already include 2 of the top 5 pharma companies where we have rolled out to patients. We provide a better solution initially in the market of specialty pharmacy where pharma manufacturers spend $3-4B+ a year on call center-based programs. Catalia Health's combination of hardware — an interactive robot that can talk with patients — and software — the artificial intelligence algorithms that generate a conversation on the fly for each patient each time — are based on the Ph.D. work of founder and CEO Cory Kidd at MIT. This combination has been proven to be more effective at creating successful outcomes than any other option currently available. The hardware is gross margin positive from day one and the margin for ongoing care is extremely high. The company has raised $9M in seed capital that brought its first products to market.

CBio (www.cbio.io)

CBio is a frontier technology company pioneering solutions across three focus areas: Research, Industrial Quality Control and Therapeutics. We leverage our proprietary live cell differentiation platform, cellPhoresis®, to identify high resolution differences in cells for our customers. Their benefit is seeing what they've been missing and the ability to make informed actionable decisions. Our first product offering is a research grade tool for academic and industry scientists. Genemod (https://www.genemod.net)

Genemod is a software startup developing the first unified platform for life scientists and researchers to collaborate and standardize their scientific research. Built for scientists, our web-based tools fit into the way individuals and teams already do their work, from restriction digest software to project and inventory management. Think Salesforce or Google Analytics for the life sciences sector with a Slack or Dropbox business model. Genemod has validated the technology and market need through partnerships with research institutions and is fundamentally transforming the $19B scientific software industry to make pre-clinical, bench research efficient and reproducible.

Greenwings-UCLA
(http://greenwingsbiomedical.com/)

Greenwings is a medical device incubator, which has teamed up with UCLA physicians to improve cost and quality of care for patients with cognitive impairment (including dementia) via improved diagnostics and informational software. Initial testing of our proprietary EEG-based diagnostic algorithm shows great potential as a clinic-based biomarker for cognitive impairment. Early tests of the technology have shown sensitivities and specificities for clinical staging of dementia ranging between 93% to 100%, which would surpass FDA OTC and CLIA Waiver requirements. Our team completed an NSF I-Corps grant in the spring of 2019 that validated a compelling customer need for informational tools and improved diagnostics for cognitive impairment among primary care providers in integrated healthcare systems in the U.S. The team has also received a Lundquist Institute seed grant, and an NIH SBIR Phase I small business grant (in addition to the NSF I-Corps grant), comprising over $200k in funding to date.

ImaginAb (www.imaginab.com)

ImaginAb is a revenue Generating LA based Biotech focused on non-invasive, whole body, in vivo PET imaging of CD8 T cells. The company's goal is to visualize the immune system's response to therapy, and thus change the way in which cancer patients are treated by tailoring immuno-oncology treatments for best patient outcomes. With our strong revenue projections, the company expect to reach financial sustainability by 2021.

Lucid Science

In partnership with Cedars-Sinai, Roche, NVidia and HTC, we have built a patent-pending virtual reality microscope that allows insurance companies to target subsets of cancer patients for testing and treatment leading to greater safety and efficacy, and value based reimbursement, as they can see 95% more of the tumor cell than they could before and predict outcome to treatment using machine learning.

Raydiant Oximetry, Inc.

(www.raydiantoximetry.com)

Raydiant Oximetry, Inc is a medical device company in the women's health care space that is developing a novel fetal monitor to more accurately detect fetal distress during labor and delivery. Current fetal monitors have a high false positive and false negative rate which leads to the overuse of medically unnecessary C-sections as well as the failed recognition of the distressed fetus. Raydiant Oximetry Sensing Systems (ROSS) will provide a more precise modality of fetal surveillance during labor and the technology was recently granted breakthrough status by the FDA for expedited market approval.

Stasis (www.stasislabs.com)

Today, doctors know more about the status of their amazon packages than they know about the status of their own patients. This information gap causes 500 patients to die everyday in US hospitals and 16% of all out-patient surgeries to be delayed. Stasis solves this by analyzing high resolution health parameters in real-time to predict patient deterioration before it happens. The company has deployed their FDA-cleared monitoring platform across international hospitals to rapidly build a proprietary dataset and iterate on AI algorithms. Stasis is developing real-time AI that can monitor patients better than having a nurse at every bedside, solving a $2.4B problem caused by clinical issues for surgery centers, while establishing partnerships to tackle the same $15B problem for hospitals.

Triton Biosystems (www.tritonbio.com)

Triton Biosystems is developing a diagnostic instrument to rapidly determine the antibiotic resistance of bacteria and fungi causing life-threatening infections. Current laboratory tests take 2-5 days to provide results, and these delays jeopardize patient safety and significantly increasing the cost of treatment. Triton Biosystems will enable lab personnel to automatically capture and analyze pathogenic microbes directly from biological fluids and swabs without the need to first grow microbes in culture. This technology will yield results in less than 90 minutes and will empower doctors to choose the right antibiotics at the right time and improve clinical outcomes. The company's core technology was developed with support from DARPA in 2016. Since, the founders have conducted over 350 interviews with key stakeholders with support from the National Science Foundation Innovation Corps. In July 2019 the company was awarded a SBIR Phase I grant from the National Science Foundation.

Veriskin, Inc. (www.veriskin.com)

Veriskin is a medical device company dedicated to facilitating and improving the accuracy of skin cancer screening. Uncertainty in the initial assessment by non-specialist caregivers leads to failure to detect skin cancer at an early, more treatable stage, malpractice claims due to false negative diagnoses and many unnecessary specialist referrals and biopsies. The TruScore is a proprietary, non-invasive, low-cost, hand-held device that aids a non-expert user to rapidly and objectively determine whether a suspect skin lesion is cancerous. The patented technology works by detecting pathological angiogenesis which is a well established hallmark of cancer. Supported by $1.9M grant award from the NIH, VeriSkin has developed a preproduction device and proprietary AI algorithm and protocols to achieve >99% sensitivity and 94% specificity in differentiating skin cancer from a variety of benign conditions as demonstrated in a clinical study on 125+ biopsy verified lesions at Sutter Health. The device is intended to be used as a decision support tool for non-specialists, e.g. nurse practitioners or primary care physicians and eventually, consumers.

90 Seconds on The Lundquist Institute



The Lundquist Institute is one of the foremost independent, non-profit research institutes in the United States.

The Lundquist Institute is an independent non-profit research institute located in the South Bay region of Los Angeles on a 72-acre campus shared with the Harbor-UCLA Medical Center.

Of the over 100 principal investigators and 400 researchers in total, many are physician-scientists who are identifying and solving problems they experience first-hand in clinics at the Medical Center.

The Lundquist Institute has a translational focus, and its innovations have led to 600 issued and pending patents and fourteen start-up companies.

The Lundquist Institute obtains ~$55,000,000 each year in NIH grant funding and sponsored research for:

- Infection and Immunity
- Translational Genomics
- Endocrinology and Metabolic Diseases
- Respiratory Medicine and Exercise Physiology
- Neurotherapeutics
- Cancer Research
- Health Services and Outcomes Research

The Lundquist Institute technologies have helped to generate numerous global medical breakthroughs including:

- The modern cholesterol test
- The conception and development of the modern-day US paramedic model of emergency patient care
- The first isolation and administration of a lung surfactant to treat premature babies
- The development of low-cost antiseptic eye drops that prevented blindness in hundreds of thousands of newborns in third-world countries
- An FDA 510k-cleared revolutionary heart monitoring medical device by QT Medical
- The FDA-approved drug Aldurazyme® for Mucopolysaccharidosis (marketed by BioMarin/Sanofi)
- An FDA-approved drug (with UCLA) to treat submental fullness (Kybella®, marketed by Allergan)
- The FDA-approved drug for the treatment for chronic pain associated with sickle-cell anemia (Endari®, marketed by Emmaus Lifesciences)

Our innovative technologies are being commercially developed by various companies; examples include:

- Novadigm is developing the first vaccine candidate (one Phase II completed, another in progress) to provide protection against both bacterial and fungal infection such as MRSA and Candida
- SyneuRx has multiple therapeutics in Phase II and II/III clinical trials for central nervous system disorders

The Lundquist Institute has dozens of technologies available for partnering across therapeutic, medical device, software, and diagnostic tool spaces.

Please use the link below and reach out to us to learn more.

https://lundquist.org/business-development-technology-transfer

We are actively seeking to form more companies and industry collaborations – both domestic and international.

Thank you.

Keith B. Hoffman, PhD
Senior Vice President
Business Development & Technology Transfer
The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center
keith.hoffman@lundquist.org
O: (310) 974-9301

BioLabs LA at The Lundquist

MRL BUILDING, 3RD FLOOR
1124 WEST CARSON STREET
TORRANCE, CA 90502

BioLabs LA at The Lundquist offers 18,000 square feet of flexible and fully equipped coworking space designed specifically to empower the development and growth of early-stage life sciences companies. Companies benefit from BioLabs' complete service offerings including wet lab space, offices, innovative programming, conference rooms, and networking opportunities.

The Lundquist Institute is an incubator of innovation with a global reach and a 67-year reputation of improving and saving lives. Driven by the positive social impacts of breakthrough therapies, the institute has over 400 researchers working on over 600 research studies. Located next to the Harbor-UCLA Medical Center, The Lundquist Institute offers core services, collaborations, and mentorship to incoming entrepreneurs.

WE ARE OPEN!

Now accepting applications and scheduling exploratory tours.

Request an invitation through Gary Olsem.

SEE THE COMPANIES MAKING LA THEIR HOME AND STAY UPDATED ON OUR UPCOMING EVENTS.

FOLLOW US!

TURNKEY OFFICE AND LAB SPACE SOLUTIONS FOR YOUR LIFE SCIENCES COMPANY NEEDS

Co-working and wet lab space in the South Bay of Los Angeles!

AMENITIES

- Flexible Membership Terms
- 24/7 Access
- Over $1M in shared equipment
- Conference Rooms
- Café and Event Space
- On-Site Concierge
- BIOCOM Membership Benefits
- Mentoring & Seminars
- Capital Connections
- Centralized & Group Purchasing
- Access to Exclusive Events

WHAT'S THE COST?

- $300 Membership Fee
- $200 – Dedicated Workstations
- $1,500 – Private Office
- $1,500 – Lab Bench
- Four private labs with 5-8 lab benches, private BSCs, etc.

biolabs

For inquires and to schedule a tour, please contact:

GARY OLSEM
Site Director
gary@biolabs.io

SPONSORED BY

WSGR BIOCOM MilliporeSigma PHCbi Promega chemometec GUNDERSON DETTMER eppendorf ThermoFisher SCIENTIFIC life technologies

The BioCenter Technology Park

at The Lundquist Institute / Harbor-UCLA



Area: 15 acres on the Western flank of the campus

Location: South Bay, Los Angeles County (City of Torrance adjacent)

Wetlab/Office Space: CEQA cleared for 250,000 sf

Key Amenities:

- First Biotech Park in the South Bay
- Significant tenant flow from 10 LA county-wide bioscience incubators
- Access to The Lundquist Institute Research Cores, including in vivo research facilities
- Active clinical trials with uniquely diverse patient population ongoing at Harbor-UCLA Medical Center
- Close proximity to LAX, Long Beach, and Orange County Airports
- Nearby affordable residential communities, highly-rated schools, world-class shopping, and beaches
- Looking for potential tenants now of 2,000 – 80,000 sq ft (Occupancy estimated late 2021)

A BIG thanks

to our generous sponsors!


THE LUNDQUIST
INSTITUTE
Research with reach.